RESUMEN

The purpose of this research was to develop a topical microsphere delivery system in a thermosensitive 20% poloxamer 407 gel (Pluronic F127) to control release of KSL-W, a cationic antimicrobial decapeptide, for a period of 4-7 days for potential application in combat related injuries. KSL-W loaded microsphere formulations were prepared by a solvent extraction-evaporation method (water-oil-water), with poly (D,L-lactic-co-glycolic acid) (PLGA) (50 : 50, low-weight, and hydrophilic end) as the polymeric system. After optimization of the process, three formulations (A, B, and C) were prepared with different organic to water ratio of the primary emulsion while maintaining other components and manufacturing parameters constant. Formulations were characterized for surface morphology, porous nature, drug loading, in vitro drug release, and antimicrobial activity. Microspheres containing 20% peptide with porous surfaces and internal structure were prepared in satisfactory yields and in sizes varying from 25 to 50 µm. Gels of 20% Pluronic F127, which were liquid at or below 24.6°C and formed transparent films at body temperature, were used as carriers for the microspheres. Rheological studies showed a gelation temperature of 24.6°C for the 20% Pluronic F127 gel alone. Gelation temperature and viscosity of formulations A, B, and C as a function of temperature were very close to those of the carrier. A Franz diffusion cell system was used to study the release of peptide from the microspheres suspended in both, phosphate-buffered saline (PBS) and a 20% Pluronic F127 gel. In vitro release of greater than 50% peptide was found in all formulations in both PBS and the gel, and in one formulation there was a release of 75% in both PBS and the gel. Fractions collected from the release process were also tested for bactericidal activity against Staphylococcus epidermidis using the broth microdilution method and found to provide effective antimicrobial activity to warrant consideration and testing in animal wound models for treating combat-related injuries.

Asunto(s)

Péptidos Catiónicos Antimicrobianos/administración & dosificación , Sistemas de Liberación de Medicamentos , Microesferas , Cicatrización de Heridas , Administración Tópica , Geles/administración & dosificación , Geles/química , Humanos , Ácido Láctico/administración & dosificación , Ácido Láctico/química , Poloxámero/administración & dosificación , Poloxámero/química , Ácido Poliglicólico/administración & dosificación , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Staphylococcus epidermidis/efectos de los fármacos , Agua/química

Asunto(s)

Péptidos Catiónicos Antimicrobianos/uso terapéutico , Cetilpiridinio/uso terapéutico , Placa Dental/prevención & control , Depsipéptidos/uso terapéutico , Péptidos Catiónicos Antimicrobianos/farmacología , Biopelículas/efectos de los fármacos , Membrana Celular/efectos de los fármacos , Cetilpiridinio/farmacología , Goma de Mascar , Recuento de Colonia Microbiana , Placa Dental/microbiología , Depsipéptidos/farmacología , Combinación de Medicamentos , Sinergismo Farmacológico , Humanos , Saliva/microbiología

RESUMEN

In the present study, the preparation and characterization of bovine serum albumin (BSA) microspheres and the evaluation of the in vitro cytotoxicity of these microspheres on acute promyelocytic leukaemia (HL-60) cells were described. Mitoxantrone (MTZ)-incorporated microspheres were evaluated for particle size, drug loading, release characteristics and surface morphology. The biological effect of MTZ released from BSA microspheres was determined on an in vitro cultured HL-60 cell line, showing that, after encapsulation, MTZ still retains cytotoxic activity. For this purpose, methyl-thiazol-tetrazolium (MTT) assay was used to evaluate the in vitro cytotoxicity of MTZ-loaded microspheres. Particle size of BSA microspheres was determined between 17.61-20.38 microm and they were smooth and spherical in shape. Encapsulation efficiency of the drug-loaded microspheres was between 22.26-60.50%. For MTZ-containing microspheres, the cell death ratios were greater than 80% for all formulations. This study demonstrate that BSA microspheres were well suited for the controlled release of MTZ and were promising for anti-cancer chemotherapy.

Asunto(s)

Antibióticos Antineoplásicos/uso terapéutico , Células HL-60/efectos de los fármacos , Leucemia Promielocítica Aguda/tratamiento farmacológico , Mitoxantrona/uso terapéutico , Animales , Antibióticos Antineoplásicos/farmacocinética , Portadores de Fármacos , Composición de Medicamentos/métodos , Humanos , Microscopía Electrónica de Rastreo , Microesferas , Mitoxantrona/farmacocinética , Tamaño de la Partícula , Albúmina Sérica Bovina , Propiedades de Superficie

RESUMEN

To evaluate the hypocalcemic effect of polyethylene gtycol-conjugated salmon calcitonins (PEG-sCT) in rats, mono-PEGylated sCTs (mono-PEG-sCTs) and unmodified sCT were administered via the intranasal route and serum calcium levels were measured by colorimetric assay using o-cresolphthalein. Mono-PEG-sCTs were prepared with different sizes of succinimidyl succinate monomethoxy PEG molecules (PEG2K), PEG5K, PEG12K) and characterized by HPLC and MALDI-TOF mass spectrometry. Nasal instillation of mono-PEG2K-sCT at a dose of 2 IU/kg resulted in sustained reduction in serum calcium levels over 8 hr, with a maximum reduction (% maxd) of 13% after 6 hr of application. Whereas unmodified sCT showed a transient decrease in serum calcium levels with the maximum reduction (5%) observed after 30 min of administration. The overall reductions in serum calcium levels expressed as the net change in AUC relative to control in 8 hr were 11.9 +/- 0.2, 4.6 +/- 0.7, and 2.6 +/- 0.7% for mono-PEG2K-, mono-PEG5K-, and mono-PEG12K-sCT, respectively, compared to 3.2 +/- 0.6% for unmodified sCT. The relative bioavailability of nasally administered 2 IU/kg of mono-PEG2K-sCT was approximately 4-fold higher than nasally administrated unmodified sCT, and the absolute bioavailability was approximately 91% of intravenously injected sCT in 8 hr. It can be concluded that the intranasal absorption of mono-PEG-sCTs was inversely related to the molecular weights of the PEG attached. Of the PEGylated sCTs examined, mono-PEG2K-sCT showed the most pronounced hypocalcemic effect. Therefore the intranasal application would probably be an alternative route of administration for mono-PEG-sCTs in achieving sustained calcium-lowering effects.

Asunto(s)

Calcitonina/administración & dosificación , Hipocalcemia/inducido químicamente , Polietilenglicoles/administración & dosificación , Administración Intranasal , Animales , Área Bajo la Curva , Disponibilidad Biológica , Calcitonina/química , Calcitonina/farmacocinética , Calcio/sangre , Cromatografía Líquida de Alta Presión , Hipocalcemia/sangre , Masculino , Peso Molecular , Polietilenglicoles/química , Polietilenglicoles/farmacocinética , Ratas , Ratas Sprague-Dawley , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción

RESUMEN

BACKGROUND: Antagonistic analogues of GnRH for the treatment of prostate cancer may be used clinically in persons for whom return to fertility after such treatment is important or desirable. The purpose of this study was, therefore, to evaluate the effects of a long term treatment with orntide, a GnRH antagonist, on testosterone levels and fertility in male rats. METHODS: Two groups of male rats received either 120-day orntide microspheres (8.8 mg orntide/kg/120 days) or vehicle alone (control group). Serum orntide and testosterone levels in both groups were monitored at certain intervals for 9 months from the initiation of treatment. After recovery of normal serum testosterone levels in the treated animals, each rat was housed with two proven breeder, but drug-naive, females. RESULTS: All mates of treated rats achieved pregnancy as rapidly as the mates of control rats although two of the control rats did not sire a litter with either female and one sired only one litter. The mean size of the litters of treated (12.3 offspring per litter) and control (10.6 offspring per litter) were similar. All offspring were grossly normal morphologically and behaviorally during the time to weaning. CONCLUSIONS: These results suggest that lack of fertility due to testosterone suppression is reversible after cessation of treatment with this GnRH antagonist.

Asunto(s)

Fertilidad/efectos de los fármacos , Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Hormona Liberadora de Gonadotropina/uso terapéutico , Orquiectomía/métodos , Animales , Antineoplásicos/efectos adversos , Antineoplásicos/uso terapéutico , Vías de Administración de Medicamentos , Femenino , Hormona Liberadora de Gonadotropina/sangre , Hormona Liberadora de Gonadotropina/farmacocinética , Hormona Liberadora de Gonadotropina/farmacología , Infertilidad Masculina/inducido químicamente , Tamaño de la Camada/efectos de los fármacos , Masculino , Microesferas , Neoplasias de la Próstata/tratamiento farmacológico , Ratas , Ratas Sprague-Dawley , Reproducción/efectos de los fármacos , Testosterona/sangre , Testosterona/metabolismo

RESUMEN

A 120-day poly(D,L-lactide) (PLA) microsphere delivery system for a luteinizing hormone-releasing hormone (LHRH) analogue, leuprolide, was prepared and evaluated. Leuprolide microspheres were prepared with PLA (m.w. 11000 Da) by a dispersion/solvent extraction-evaporation method and characterized for drug load by HPLC, particle size by laser diffractometry and surface morphology by scanning electron microscopy. In vitro peptide release and polymer degradation were studied using a modified dialysis method. Serum peptide and testosterone levels were analyzed after subcutaneous administration using a rat model. Spherical microspheres with a mean diameter of 52 microm containing 13.4% peptide released 10% of the peptide within 24 h, followed by a linear release for 150 days. Serum leuprolide levels increased immediately after administration of the microspheres to 45.6 ng/ml, but then fell to 4.3 ng/ml at 15 days and approximately 2.0 ng/ml at 30 days where they remained for 120 days. The testosterone levels increased initially to 15 ng/ml and then decreased to below 0.5 ng/ml by day 4 where they remained for 120 days. In conclusion, a 120-day microsphere formulation of leuprolide was developed with excellent controlled peptide release characteristics and in vivo efficacy.

Asunto(s)

Leuprolida/administración & dosificación , Poliésteres/administración & dosificación , Animales , Concentración de Iones de Hidrógeno , Leuprolida/sangre , Leuprolida/química , Masculino , Microesferas , Peso Molecular , Ratas , Ratas Sprague-Dawley , Solubilidad , Testosterona/sangre

RESUMEN

PURPOSE: The purpose of this study was to develop a polymeric sustained delivery system for recombinant human bone morphogenetic protein-2 (BMP-2) and to evaluate local bone growth induced by the sustained release of BMP-2 in an animal model. METHODS: BMP-2 was incorporated in biodegradable poly(D,L-lactide-co-glycolide) (PLGA) microspheres to obtain different release rates. Two sustained and an immediate release implants were produced by suspending the BMP-2 loaded PLGA microspheres in aqueous sodium carboxymethylcellulose (CMC), lyophilizing, and cutting the dried materials to the size of the animal bone defects. The local in vivo release at the implantation site in rat calvarial defects was determined by gamma scintigraphy using radiolabeled BMP-2. The local bone induction in the critical size of rabbit calvarial defects was evaluated six weeks post implantation. RESULTS: The immediate release implant showed about 65% initial drug release within 24 h and the remaining BMP-2 quickly exhausted from the implantation site within 7 days. The sustained release implants, showing 45-55% initial release followed by a prolonged release for 21 days, released a greater amount of BMP-2 at the implantation site and maintained higher serum BMP-2 for the longer period of time compared to the immediate release implant. Significant bone growth was observed in all BMP-2 treated defects while the defects without treatment or with BMP-2-free implant showed minimal bone healing. 75-79% of rabbit calvarial defect area was healed with newly induced bone matrix by the sustained release implants in 6 weeks as compared to 45% recovery from the immediate release implant. CONCLUSION: The sustained delivery of BMP-2 based on the biodegradable PLGA microsphere system resulted in faster and more complete bone healing in the animal model.

Asunto(s)

Materiales Biocompatibles/farmacología , Proteínas Morfogenéticas Óseas/farmacología , Ácido Láctico/farmacología , Ácido Poliglicólico/farmacología , Polímeros/farmacología , Cráneo/efectos de los fármacos , Factor de Crecimiento Transformador beta , Animales , Proteína Morfogenética Ósea 2 , Preparaciones de Acción Retardada , Masculino , Microesferas , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Conejos , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes/farmacología , Cráneo/patología , Factores de Tiempo

RESUMEN

PURPOSE: This study was done to prepare, characterize, and evaluate salmon calcitonin (sCT) microspheres (ms) in vivo using a low molecular weight, hydrophilic 50:50 poly (D,L-lactide-co-glycolide) polymer (PLGA). METHODS: sCT ms were prepared by a dispersion/solvent extraction/evaporation process and characterized for drug content, particle size, surface morphology, and structural integrity of encapsulated peptide. Peptide stability and binding to the polymer was studied in 0.1 M phosphate buffer (PB), pH 7.4, and 0.1 M acetate buffer (AB), pH 4.0. Serum sCT levels were monitored for 2 weeks after subcutaneous injection of sCT ms to rats. RESULTS: sCT ms were essentially free of discernible surface pores with a particle size distribution in the range of 16 to 89 mm and mean particle size of 51 and 53 mm for 2 batches. Fourier Transform Matrix-assisted Laser Desorption mass spectrometry of the extracted peptide showed that the encapsulation process did not alter its chemical structure. The peptide was substantially more stable in AB than in PB. Peptide binding to the polymer was dependent on pH and was markedly higher in PB than in AB. In vivo study proved that elevated serum sCT levels could be sustained for at least 10 days after administration of sCT ms to rats at a dose of 1.0 mg/kg. CONCLUSIONS: It was demonstrated that sCT could be incorporated into polymeric ms prepared from a low molecular weight, hydrophilic PLGA using a dispersion technique without altering molecular structure. A 2-week formulation was prepared at a dose of 1.0 mg/kg.

Asunto(s)

Calcitonina/administración & dosificación , Microesferas , Animales , Calcitonina/sangre , Calcitonina/química , Preparaciones de Acción Retardada , Portadores de Fármacos , Femenino , Ácido Láctico/química , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/química , Ratas , Ratas Sprague-Dawley

RESUMEN

This research compared the binding and release of recombinant human bone morphogenetic protein 2 (rhBMP-2) with a series of hydrophobic and hydrophilic poly-lactide-co-glycolide (PLGA) copolymers. Porous microspheres were produced via a double emulsion process. Binding and incorporation of protein were achieved by soaking microspheres in buffered protein solutions, filtering, and comparing protein concentration remaining to nonmicrosphere-containing samples. Protein release was determined by soaking bound microspheres in a physiological buffer and measuring protein concentration (by reversed-phase high-performance liquid chromatography) in solution over time. Normalized for specific surface area and paired by polymer molecular weight, microspheres made from hydrophilic 50:50 or 75:25 PLGA bound significantly more protein than microspheres made from the corresponding hydrophobic PLGA. Increased binding capacity correlated with higher polymer acid values. With certain polymers, rhBMP-2 adsorption was decreased or inhibited at high protein concentration, but protein loading could be enhanced by increasing the protein solution:PLGA (volume:mass) ratio or by repetitive soaking. Microspheres of various PLGAs released unbound protein in 3 days, whereas the subsequent bound protein release corresponded to mass loss. RhBMP-2 binding to PLGA was controlled by the acid value, protein concentration, and adsorption technique. The protein released in 2 phases; the first occurred over 3 days regardless of PLGA used and emanated from unbound, incorporated protein, while the second was controlled by mass loss and therefore was dependent on the polymer molecular weight. Overall, control of rhBMP-2 delivery is achievable by selection of PLGA microsphere carriers.

Asunto(s)

Proteínas Morfogenéticas Óseas/administración & dosificación , Ácido Láctico/química , Microesferas , Ácido Poliglicólico/química , Polímeros/química , Factor de Crecimiento Transformador beta , Adsorción , Proteína Morfogenética Ósea 2 , Proteínas Morfogenéticas Óseas/genética , Proteínas Morfogenéticas Óseas/metabolismo , Portadores de Fármacos , Ácido Láctico/metabolismo , Ácido Poliglicólico/metabolismo , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/metabolismo , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/metabolismo

RESUMEN

The hypothesis of this research was that implants of poly(lactide-co-glycolide) (PLGA) microspheres loaded with bone morphogenetic protein-2 (rhBMP-2) and distributed in a freeze-dried carboxymethylcellulose (CMC) matrix would produce more new bone than would matrix implants of non-protein-loaded microspheres or matrix implants of only CMC. To test this hypothesis it was necessary to fashion microsphere-loaded CMC implants that were simple to insert, fit precisely into a defect, and would not elicit swelling. Microspheres were produced via a water-in-oil-in-water double-emulsion system and were loaded with rhBMP-2 by soaking them in a buffered solution of the protein at a concentration of 5.4 mg protein per gram of PLGA. Following recovery of the loaded microspheres by lyophilization, matrices for implantation were prepared by lyophilizing a suspension of the microspheres in 2% CMC in flat-bottom tissue culture plates. Similar matrices were made with 2% CMC and with 2% CMC containing blank microspheres. A full-thickness calvarial defect model in New Zealand white rabbits was used to assess bone growth. Implants fit the defect well, allowing for direct application. Six weeks postsurgery, defects were collected and processed for undecalcified histology. In vitro, 60% of the loaded rhBMP-2 released from devices or microspheres in 5 to 7 days, with the unembedded microspheres releasing faster than those embedded in CMC. In vivo, the rhBMP-2 microspheres greatly enhanced bone healing, whereas nonloaded PLGA microspheres in the CMC implants had little effect. The results showed that a lyophilized device of rhBMP-2/PLGA microspheres in CMC was an effective implantable protein-delivery system for use in bone repair.

Asunto(s)

Proteínas Morfogenéticas Óseas/administración & dosificación , Regeneración Ósea/efectos de los fármacos , Carboximetilcelulosa de Sodio , Ácido Láctico , Microesferas , Ácido Poliglicólico , Polímeros , Factor de Crecimiento Transformador beta , Animales , Proteína Morfogenética Ósea 2 , Proteínas Morfogenéticas Óseas/genética , Proteínas Morfogenéticas Óseas/metabolismo , Portadores de Fármacos , Implantes de Medicamentos , Liofilización , Humanos , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Conejos , Proteínas Recombinantes/administración & dosificación

Asunto(s)

Coloides/química , Liofilización/instrumentación , Celulosa/química , Celulosa/aislamiento & purificación , Estudios de Factibilidad , Liofilización/métodos , Microesferas , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/métodos

Asunto(s)

Composición de Medicamentos/instrumentación , Composición de Medicamentos/métodos , Microesferas , Tecnología Farmacéutica/instrumentación , Tecnología Farmacéutica/métodos , Desecación/instrumentación , Desecación/métodos , Estudios de Factibilidad , Tamaño de la Partícula , Vacio

RESUMEN

This study evaluated the effect of parathyroid hormone (PTH) infusion alone or in combination with salmon calcitonin (sCT) in ovariectomized (OVX) rats and compared it with daily PTH injections alone or in combination with sCT infusion. Female Sprague-Dawley rats were divided randomly into 6 groups and were either bilaterally ovariectomized or underwent a sham operation; they were then treated for 4 weeks, beginning the day after surgery. Each group of OVX rats received either PTH infusion (group 1), PTH + sCT infusion (group 2), sCT infusion + daily PTH injection (group 3), or daily PTH injection (group 4). One group each of OVX (group 5) and sham-operated rats (group 6) received daily injections of vehicle alone. PTH was injected at 80 microg/kg/day and infused at 40 microg/kg/day, whereas sCT was infused at 10 microg/kg/day. The animals were sacrificed 28 days after treatment, and cancellous bone volume was measured in the tibial metaphysis. Similar to daily PTH injections, continuous infusion of PTH alone increased cancellous bone volume significantly over that seen in vehicle-treated OVX and sham-operated rats. Although cancellous bone volume after continuous infusion of PTH + sCT was also significantly higher than that seen in vehicle-treated OVX and sham-operated rats, the increase was significantly lower than with the other 3 nonvehicle treatments. The increase in cancellous bone volume after administration of sCT infusion along with daily PTH injections was not different from that with daily PTH injections alone. Thus, at the doses tested, the beneficial effects of PTH injection were not apparently improved by PTH infusion or by combination with sCT.

Asunto(s)

Huesos/efectos de los fármacos , Calcitonina/administración & dosificación , Hormona Paratiroidea/farmacología , Fragmentos de Péptidos/farmacología , Analgésicos/administración & dosificación , Animales , Densidad Ósea/efectos de los fármacos , Huesos/anatomía & histología , Calcitonina/sangre , Evaluación Preclínica de Medicamentos , Femenino , Bombas de Infusión Implantables , Infusiones Intravenosas , Inyecciones Intravenosas , Ósmosis , Ovariectomía , Hormona Paratiroidea/administración & dosificación , Hormona Paratiroidea/sangre , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/sangre , Ratas , Ratas Sprague-Dawley , Tibia/anatomía & histología , Tibia/efectos de los fármacos

RESUMEN

PURPOSE: To prepare and characterize a novel composite microsphere system based on poly(D,L-lactide-co-glycolide) (PLGA) and poly(acryloyl hydroxyethyl starch) (acHES) hydrogel for controlled protein delivery. METHODS: Model proteins, bovine serum albumin, and horseradish peroxidase were encapsulated in the acHES hydrogel, and then the protein-containing acHES hydrogel particles were fabricated in the PLGA matrix by a solvent extraction or evaporation method. The protein-loaded PLGA-acHES composite microspheres were characterized for protein loading efficiency, particle size, and in vitro protein release. Protein stability was examined by size-exclusion chromatography, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and monitoring the enzymatic activity. RESULTS: Scanning electron microscopy showed discrete PLGA microspheres containing many acHES particles. The composite microspheres were spherical and smooth in size range of 39-93 microm. The drug loading efficiency ranged from 51 to 101%. The composite microspheres showed more favorable in vitro release than conventional PLGA microspheres. The composite microspheres showed 20% less initial with a gradual sustained release compared to high burst (approximately 60%) followed by a very slow release with the conventional PLGA microspheres. The composite microspheres also stabilized encapsulated proteins from the loss of activity during the microsphere preparation and release. Proteins extracted from the composite microspheres showed good stability without protein degradation products and structural integrity changes in the size-exclusion chromatography and SDS-PAGE analyses. Horseradish peroxidase extracted from microspheres retained more than 81% enzymatic activity. CONCLUSION: The PLGA-acHES composite microsphere system could be useful for the controlled delivery of protein drugs.

Asunto(s)

Resinas Acrílicas/química , Ácido Láctico/química , Ácido Poliglicólico/química , Polímeros/química , Proteínas/administración & dosificación , Proteínas/química , Almidón/química , Fenómenos Químicos , Química Física , Composición de Medicamentos , Estabilidad de Medicamentos , Electroforesis en Gel de Poliacrilamida , Peroxidasa de Rábano Silvestre/química , Hidrogel de Polietilenoglicol-Dimetacrilato , Microscopía Electrónica de Rastreo , Microesferas , Tamaño de la Partícula , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Albúmina Sérica Bovina/química , Compuestos de Vinilo/química

RESUMEN

PURPOSE: To prepare, characterize and evaluate in vitro sustained delivery formulations for a novel LHRH antagonist, Orntide acetate, using biodegradable microspheres (ms). METHODS: Poly(d,l-lactide) (PLA) and poly(d,l-lactide-co-glycolide) (PLGA) were characterized for molecular weight (Mw, Mn) using gel permeation chromatography (GPC) and content of free end carboxyl groups (acid number, AN) by a titration method. 1- and 4-month Orntide ms were prepared by a dispersion/solvent extraction/evaporation process and characterized for drug content (HPLC), bulk density (tapping method), particle size (laser diffraction method), surface morphology (scanning electron microscopy, SEM), and structural integrity of encapsulated peptide by Fourier Transform Matrix Assisted Laser Desorption mass spectrometry (FT-MALDI). Peptide binding to PLA and PLGA and non-specific adsorption to blank ms was studied in 0.1 M phosphate buffer pH 7.4 (PB) and 0.1 M acetate buffer pH 4.0 (AB). In vitro release of peptide was assessed in PB and AB. RESULTS: Mw for the PLGA copolymers varied from 10,777 to 31,281 Da and was 9,489 Da for PLA. AN was between 4.60 and 15.1 for the hydrophilic resomers and 0.72 for the hydrophobic 50:50 PLGA copolymer. Spherical ms (3.9 mu to 14 mu in diameter) with mostly nonporous surface and varying degree of internal porosity were prepared. FT-MALDI mass spectra of the extracted peptide showed that the encapsulation process did not alter its chemical structure. Peptide binding to PLGA and PLA and non-specific adsorption to blank PLGA ms were dependent upon pH and were markedly higher in PB than in AB. The initial in vitro release in PB varied from 0.5 to 26%/24 h but due to substantial binding of the peptide to the polymeric matrix the long-term release in PB could not be determined. Application of a dialysis method allowed for a more accurate determination of in vitro release and a good total drug recovery. CONCLUSIONS: Orntide acetate was successfully incorporated into PLA and PLGA ms and the 1- and 4-month in vitro release profiles were achieved by polymer selection and optimization of the manufacturing parameters.

Asunto(s)

Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/administración & dosificación , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Ácido Láctico/administración & dosificación , Poliésteres/administración & dosificación , Ácido Poliglicólico/administración & dosificación , Polímeros/administración & dosificación , Concentración de Iones de Hidrógeno , Microesferas , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Factores de Tiempo

RESUMEN

The purpose of this study was to evaluate the utility of combining polymer matrices to overcome extended lag periods or unacceptably short durations of action intrinsic in the individual polymer systems. Leuprolide, an LHRH superagonist, was incorporated into a variety of poly(lactide-co-glycolide) (PLGA) matrices using a solvent extraction/evaporation method. The in vitro release of Leuprolide from these matrices was evaluated at pH 7.0 and 37 degrees C in phosphate buffer. The formulations were administered to an animal model at 3 or 9 mg kg(-1) doses and serum testosterone levels were followed using a RIA method. A two-part system was made by combining microspheres made from a 75:25 acid terminated PLGA and microspheres made from a 75:25 ester terminated PLGA. This combination elicited chemical castration from 10-100 days. A three-part combination composed of an ester terminated 75:25 PLGA formulation, an ester terminated 50:50 PLGA formulation and an acid terminated 50:50 PLGA formulation also provided a composite profile with an onset of 10 days and a duration of approximately 100 days. Additionally, a single polymer system composed of a high molecular weight ester terminated 75:25 PLGA was employed to produce release over the desired 90-day release period. This study demonstrates that microsphere combinations can potentially provide effective therapies over extended intervals when combined at the proper ratio.

Asunto(s)

Materiales Biocompatibles , Ácido Láctico , Leuprolida/administración & dosificación , Ácido Poliglicólico , Polímeros , Animales , Cromatografía Líquida de Alta Presión , Portadores de Fármacos , Inyecciones , Leuprolida/farmacocinética , Leuprolida/farmacología , Microesferas , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas , Ratas Sprague-Dawley , Testosterona/sangre

RESUMEN

The objective of this study was to evaluate the effect of polymer and microsphere blending in achieving both a sufficient initial release and a desired continuous release of a peptide from poly(D, L-lactide-co-glycolide) microspheres. Leuprolide acetate loaded hydrophilic 50:50 PLGA microspheres were prepared by a solvent-extraction/evaporation process and were characterized for their drug load, bulk density, size distribution, surface area, surface morphology, in vitro drug release, and in vivo efficacy. Combining PLGA polymers that varied in their molecular weights in various ratios yielded microspheres with varied drug release profiles commensurate with the hydration tendencies of the polymers. Increasing the component of lower molecular weight 50:50 hydrophilic PLGA polymer, 8.6 kDa increased the initial drug release. A similar microsphere formulation prepared instead with blending microspheres from individual polymers showed a similar increase. In an animal model, microspheres obtained from polymer or microsphere blends attained a faster onset of testosterone suppression as compared to microspheres from higher molecular weight 50:50 hydrophilic PLGA polymer, 28.3 kDa, alone. These studies illustrated the feasibility of blending polymers or microspheres of varied characteristics in achieving modified drug release. In particular the increased initial release of the peptide could help avoid the therapeutic lag phase usually observed with microencapsulated macromolecules.

Asunto(s)

Ácido Láctico/administración & dosificación , Leuprolida/administración & dosificación , Ácido Poliglicólico/administración & dosificación , Polímeros/administración & dosificación , Animales , Química Farmacéutica , Masculino , Microesferas , Peso Molecular , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ratas , Ratas Sprague-Dawley , Testosterona/sangre , Viscosidad

RESUMEN

PURPOSE: The purpose of this study was to investigate the effect of a novel LHRH antagonist, Orntide acetate, on the initial testosterone elevation in rats during treatment with a LHRH superagonist, Leuprolide acetate. METHODS: Thirteen groups of a rat animal model were administered either liquid Orntide or Orntide PLGA microspheres before or simultaneously with Leuprolide injections. Serum levels of testosterone were monitored during the time course of the study using a radioimmunoassay method. RESULTS: Administration of a single daily dose of liquid Orntide resulted in testosterone suppression within 6 h to levels below 0.5 ng/ml (castration level). However, combined administration of liquid Orntide and liquid Leuprolide did not have a significant effect on the initial testosterone elevation in studied rats. Similarly, there was no effect when liquid Orntide was co-administered with Leuprolide microspheres. Administration of Orntide microspheres 48 h before Leuprolide microspheres suppressed testosterone levels below the castration level within 24 h, however, did not prevent a rise in testosterone serum concentration upon administration of Leuprolide microspheres. Also, a second testosterone peak was observed between days 3 and 15 in the animals which were simultaneously treated with Orntide microspheres and Leuprolide microspheres. CONCLUSIONS: Orntide acetate was found to be an effective LHRH antagonist with a rapid onset of pharmacological action and a short biological half-life. Administration of a single dose of liquid Orntide or Orntide microspheres, resulted in rapid testosterone suppression without an initial elevation, as seen with LHRH superagonists. However, combined administration of Orntide and Leuprolide did not have an effect on the initial testosterone elevation in rats.

Asunto(s)

Hormona Liberadora de Gonadotropina/análogos & derivados , Hormona Liberadora de Gonadotropina/agonistas , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Leuprolida/farmacología , Animales , Hormona Liberadora de Gonadotropina/farmacología , Masculino , Ratas , Ratas Sprague-Dawley , Testosterona/sangre

RESUMEN

The objective of this study was to evaluate formulation variables such as drug load and addition of a porosigen in achieving an increased initial release of peptide from poly(d,l-lactide-co-glycolide) (PLGA) microspheres by altering carrier characteristics. Leuprolide acetate-loaded PLGA microspheres were prepared by a solvent-extraction-evaporation process and were characterized for their drug load (HPLC assay), bulk density (tapping method), size distribution (dynamic light scattering), specific surface area (Brunauer-Emmett-Teller [BET] analysis), surface morphology (scanning electron microscopy), in vitro drug release (at 37 degrees C), and in vivo efficacy (suppression of rat serum testosterone). Increasing the drug load, and adding various amounts of calcium chloride to organic and aqueous phases of the emulsion during processing yielded particles with increased porosity, lower bulk density, higher specific surface area, and accordingly higher initial release. In an animal model, these formulations showed a faster onset of testosterone suppression compared to microspheres without higher drug load or calcium chloride. The approaches employed in this study were found to be effective in avoiding the therapeutic lag phase usually observed with microencapsulated macromolecular drugs.

Asunto(s)

Ácido Láctico , Péptidos/administración & dosificación , Ácido Poliglicólico , Polímeros , Animales , Antineoplásicos Hormonales/administración & dosificación , Antineoplásicos Hormonales/química , Antineoplásicos Hormonales/farmacocinética , Cloruro de Calcio , Portadores de Fármacos , Leuprolida/administración & dosificación , Leuprolida/química , Leuprolida/farmacocinética , Masculino , Microscopía Electrónica de Rastreo , Microesferas , Tamaño de la Partícula , Péptidos/química , Péptidos/farmacocinética , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Porosidad , Ratas , Ratas Sprague-Dawley , Propiedades de Superficie

RESUMEN

The purpose of this study was to develop and evaluate a dialysis in vitro release technique for peptide-containing poly(d, l-lactide-co-glycolide) (PLGA) microspheres (ms) that would correlate with in vivo data. Using a luteinizing hormone- releasing hormone analogue (LHRH), Orntide acetate, solubility and stability were determined in 0.1 M phosphate buffer (PB), pH 7.4, and in 0.1 M acetate buffer (AB), pH 4.0, with high-performance liquid chromotography (HPLC), and peptide permeability through a dialysis membrane (molecular weight cut-off 300,000) was determined. Orntide ms were prepared by a dispersion/solvent extraction/evaporation method and characterized for drug content (HPLC), particle size distribution (laser diffraction method), and surface morphology (scanning electron microscopy). In vitro release was studied in PB using a conventional extraction method and with a new dialysis method in AB. Gravimetric analyses of polymer mass loss and matrix hydration, and peptide adsorption to blank PLGA ms (50:50, M(w) 28 022) were carried out in PB and AB upon incubation at 37 degrees C. Serum Orntide and testosterone levels in rats after administration of Orntide ms were determined by radioimmunoassay. Orntide acetate solubility was influenced by pH; approximately 2.3 mg/mL dissolved in PB and > 18 mg/mL in AB. Stability was pH- and temperature-dependent. The peptide was very stable at pH 4.0, 4 degrees C, but degraded rapidly at pH 7.4, 37 degrees C. Peptide permeability through the dialysis membrane was accelerated by agitation and >95% equilibrium was reached within 48 hours. The overall release rate was higher with the dialysis method. Mass loss of the Orntide ms was faster in AB (50% loss in 3 weeks; 95% in 35 days) than in PB (65% in 35 days). In contrast, hydration after 35 days was 4-fold higher in PB. The nonspecific adsorption to blank ms was greater in PB (128 microg Orntide/10 mg PLGA) compared with AB (< 5 microg Orntide/ 10 mg PLGA). Administration of 30-day Orntide PLGA ms to rats resulted in an initial serum Orntide level of 21 ng/mL after 6 hours and a Cmax of 87 ng/mL after 6 days. Testosterone levels were suppressed immediately after ms administration (3 mg Orntide /Kg) from 5.2 ng/mL to 0.3 ng/mL (after 24 hours) and remained suppressed for 38 days. Orntide acetate solubility and degradation kinetics were markedly influenced by pH of the buffer systems and mass loss; matrix hydration, as well as the nonspecific adsorption to blank ms, was pH-dependent. The in vitro release profile obtained with the dialysis method in AB correlated well with the in vivo data, thereby providing a more reliable prediction of in vivo performance.

Asunto(s)

Materiales Biocompatibles/química , Hormona Liberadora de Gonadotropina/análogos & derivados , Microesferas , Péptidos/metabolismo , Adsorción , Animales , Preparaciones de Acción Retardada , Diálisis , Hormona Liberadora de Gonadotropina/sangre , Hormona Liberadora de Gonadotropina/química , Hormona Liberadora de Gonadotropina/metabolismo , Hormona Liberadora de Gonadotropina/farmacología , Ácido Láctico/química , Ácido Láctico/metabolismo , Masculino , Membranas Artificiales , Peso Molecular , Péptidos/química , Péptidos/farmacocinética , Permeabilidad , Ácido Poliglicólico/química , Ácido Poliglicólico/metabolismo , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/química , Polímeros/metabolismo , Ratas , Ratas Sprague-Dawley , Solubilidad , Testosterona/sangre